Lobular Carcinoma In Situ (LCIS) / High-Risk Lobular Lesions
LCIS is a high-risk finding involving abnormal cells in the breast lobules. It is not invasive breast cancer, but it is associated with an increased risk of developing breast cancer in either breast over time. LCIS is often discovered incidentally on biopsy performed for another reason.
At The Medical Group of New Jersey, we provide personalized guidance on surveillance, prevention, and when surgical excision is recommended based on the specific subtype and biopsy details.
Symptom Onset & Initial Evaluation
Lobular carcinoma in situ (LCIS) is considered a high-risk breast condition, rather than an invasive cancer. In most cases, LCIS does not cause symptoms and is often discovered incidentally during a biopsy performed for another breast abnormality.
LCIS is most commonly identified after:
- Biopsy of an abnormal finding on breast imaging, such as a mammogram or ultrasound
- Evaluation of another high-risk breast lesion detected during screening
During your consultation, your breast surgeon will carefully review the pathology results, including whether the finding represents classic LCIS or a higher-risk subtype such as pleomorphic LCIS. Imaging studies are also reviewed to ensure that the biopsy findings match what was seen on mammography or other imaging tests.
Your surgeon will also evaluate individual risk factors, including family history of breast cancer, prior biopsies, and genetic risk factors, to help guide the next steps in care.
Diagnosis
The diagnosis of LCIS is based on microscopic examination of breast tissue obtained during a biopsy.
Diagnostic evaluation typically includes:
- Core needle biopsy pathology, which confirms the presence of LCIS cells within the breast lobules
- Determining whether the finding represents classic LCIS or a more concerning subtype that may require additional treatment
- Careful imaging review, ensuring that the pathology findings are consistent with the abnormality seen on imaging (known as imaging-pathology concordance)
These factors help your care team determine whether further surgical evaluation is necessary.
Treatment & Ongoing Management
Management of LCIS focuses on ensuring an accurate diagnosis and addressing future breast cancer risk. Treatment recommendations depend on the specific subtype of LCIS and the overall clinical picture.
Management strategies may include:
- Surgical excision when pathology suggests a higher-risk subtype (such as pleomorphic LCIS) or when imaging and biopsy findings are not clearly consistent
- When classic LCIS is confirmed, treatment often focuses on long-term monitoring and risk management rather than immediate surgery
Your care plan may include:
- Enhanced breast screening, which may involve more frequent mammography or additional imaging
- Risk-reduction counseling, including discussion of lifestyle factors and preventive strategies
- Preventive medications, when appropriate, to reduce the risk of future breast cancer
- A personalized surveillance plan based on individual risk assessment tools and medical history
Follow-Up Care
Patients diagnosed with LCIS typically follow a structured surveillance program designed to monitor breast health over time.
Follow-up care often includes:
- Regular breast imaging, such as mammography and, in some cases, MRI
- Routine clinical breast examinations
- Ongoing risk assessment and preventive care planning
With careful monitoring and preventive strategies, many patients with LCIS are able to maintain long-term breast health while minimizing future cancer risk.